Results 191 to 200 of about 38,393 (221)
Some of the next articles are maybe not open access.
Clinical Drug Investigation, 2002
The thiazolidinediones troglitazone, rosiglitazone and pioglitazone reduce insulin resistance by altering gene expression involved in glucose and lipid metabolism, via binding to peroxisome proliferator-activated receptor γ. Thiazolidinediones show additive therapeutic effects when combined with metformin, a sulphonylurea or insulin, and have potential
A K, Vaish, C G, Agarwal
openaire +3 more sources
The thiazolidinediones troglitazone, rosiglitazone and pioglitazone reduce insulin resistance by altering gene expression involved in glucose and lipid metabolism, via binding to peroxisome proliferator-activated receptor γ. Thiazolidinediones show additive therapeutic effects when combined with metformin, a sulphonylurea or insulin, and have potential
A K, Vaish, C G, Agarwal
openaire +3 more sources
Expert Opinion on Drug Safety, 2012
Thiazolidinediones (TZDs) initially showed great promise as unique receptor-mediated oral therapy for type 2 diabetes, but a host of serious side effects, primarily cardiovascular, have limited their utility. It is crucial at this point to perform a risk-benefit analysis to determine what role TZDs should play in our current treatment of type 2 ...
Jacqueline, Kung, Robert R, Henry
openaire +2 more sources
Thiazolidinediones (TZDs) initially showed great promise as unique receptor-mediated oral therapy for type 2 diabetes, but a host of serious side effects, primarily cardiovascular, have limited their utility. It is crucial at this point to perform a risk-benefit analysis to determine what role TZDs should play in our current treatment of type 2 ...
Jacqueline, Kung, Robert R, Henry
openaire +2 more sources
Thiazolidinediones and inflammation
Lupus, 2005Thiazolidinediones (TZDs) are selective ligands of peroxisome-proliferator-activated receptor g increasingly used in the treatment of type 2 diabetes. Both in vitro and in vivo studies provide evidence that TZDs have anti-inflammatory properties. TZDs inhibit macrophage activation and decrease inflammatory cytokine expression and release in macrophage
CONSOLI, Agostino, DEVANGELIO, ELEONORA
openaire +3 more sources
Endocrinology and Metabolism Clinics of North America, 1997
The thiazolidinediones are a unique class of compounds that exert direct effects on the mechanisms of insulin resistance and result in improved insulin action and reduced hyperinsulinemia. Troglitazone is the first of these compounds to be approved for use in humans and has the potential not only to reduce glycemia and insulin requirements in type II ...
openaire +2 more sources
The thiazolidinediones are a unique class of compounds that exert direct effects on the mechanisms of insulin resistance and result in improved insulin action and reduced hyperinsulinemia. Troglitazone is the first of these compounds to be approved for use in humans and has the potential not only to reduce glycemia and insulin requirements in type II ...
openaire +2 more sources
The Lancet, 2000
Thiazolidinediones, which are being developed for the treatment of insulin resistance and type 2 diabetes mellitus, bind and activate peroxisome proliferator-activated receptor gamma, a nuclear receptor that regulates the expression of several genes involved in metabolism.
K, Schoonjans, J, Auwerx
openaire +2 more sources
Thiazolidinediones, which are being developed for the treatment of insulin resistance and type 2 diabetes mellitus, bind and activate peroxisome proliferator-activated receptor gamma, a nuclear receptor that regulates the expression of several genes involved in metabolism.
K, Schoonjans, J, Auwerx
openaire +2 more sources
Nihon rinsho. Japanese journal of clinical medicine, 2007
Sunder Mudaliar, Robert Henry
+7 more sources
Sunder Mudaliar, Robert Henry
+7 more sources
Thiazolidinedione‐Induced Edema
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2002Edema is an adverse event associated with thiazolidinedione therapy. The potential for mild‐to‐moderate peripheral edema with thiazolidinedione is known, especially in patients who have heart failure or use insulin. Our experience reveals that patients who do not have heart failure or do not use insulin also can develop moderate‐to‐severe edema that ...
Nancee V, Niemeyer, Laurel M, Janney
openaire +2 more sources
Nonhypoglycemic Effects of Thiazolidinediones
Annals of Internal Medicine, 2001The thiazolidinediones are a new class of compounds for treatment of type 2 diabetes. Troglitazone became available in the United States in 1997 but was withdrawn from the market in March 2000 because it caused severe idiosyncratic liver injury. Rosiglitazone and pioglitazone have been available since 1999.
J M, Quesada-Gómez, I, Serrano-Alferez
openaire +4 more sources
Vascular reactivity and thiazolidinediones
The American Journal of Medicine, 2003Endothelial dysfunction is a critical factor in the development of vascular disease in patients with diabetes mellitus. Maintenance of the vascular tone and luminal diameter of a blood vessel is dependent on the net balance of vasoconstrictor and vasodilator forces. In both diabetes and obesity, vascular reactivity is abnormal.
Paresh, Dandona +2 more
openaire +2 more sources